Thirty-two patients with nonpancreatic neuroendocrine tumors, three of whom had high-grade NECC, were included in a phase II basket trial using dual therapy with anti-CTLA-4 and anti-PD-1 inhibitors in treating uncommon cancers (DART SWOG 1609). Here, PDCD1 is linked to cancer.